Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.

TitleMemantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.
Publication TypeJournal Article
Year of Publication2008
AuthorsGlodzik L, King KG, Gonen O, Liu S, de Santi S, de Leon MJ
JournalProg Neuropsychopharmacol Biol Psychiatry
Volume32
Issue4
Pagination1005-12
Date Published2008 May 15
ISSN0278-5846
KeywordsAdult, Aged, Aging, Alzheimer Disease, Cognition Disorders, Excitatory Amino Acid Antagonists, Female, Glutamic Acid, Hippocampus, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Male, Memantine
Abstract

Glutamate (Glu) is associated with excitotoxic cell damage. Memantine modulates the glutamate induced excitotoxicity in Alzheimer's disease (AD). No information is available as to the influence of memantine on in vivo brain glutamate levels. Hippocampal Glu levels were measured in cognitively impaired and normal individuals (n=10) before and after 6 months of memantine treatment, using three dimensional high spatial resolution (0.5 cm(3) voxels) proton magnetic resonance spectroscopy at 3 T. These measurements were also repeated in a non-treated cognitively normal group (n=6). Treatment with memantine decreased Glu/Cr (creatine) ratio in the left hippocampal region. Memantine reduced hippocampal glutamate levels, which may be consistent with its anti-excitotoxic property.

DOI10.1016/j.pnpbp.2008.01.016
Alternate JournalProg Neuropsychopharmacol Biol Psychiatry
PubMed ID18343551
PubMed Central IDPMC2789554
Grant ListR01 EB001015 / EB / NIBIB NIH HHS / United States
M01 RR000096-458307 / RR / NCRR NIH HHS / United States
M01RR00096 / RR / NCRR NIH HHS / United States
EB01015 / EB / NIBIB NIH HHS / United States
R01 EB001015-12 / EB / NIBIB NIH HHS / United States
R01 NS050520-04 / NS / NINDS NIH HHS / United States
P30 AG008051-189005 / AG / NIA NIH HHS / United States
AG12101 / AG / NIA NIH HHS / United States
R01 NS050520 / NS / NINDS NIH HHS / United States
R01 AG022374 / AG / NIA NIH HHS / United States
R01 AG012101-13 / AG / NIA NIH HHS / United States
M01 RR000096 / RR / NCRR NIH HHS / United States
NS050520 / NS / NINDS NIH HHS / United States
P30 AG008051 / AG / NIA NIH HHS / United States
R01 AG022374-02 / AG / NIA NIH HHS / United States
P30 AG08051 / AG / NIA NIH HHS / United States
R01 AG012101-14 / AG / NIA NIH HHS / United States
AG 22374 / AG / NIA NIH HHS / United States
R01 AG012101 / AG / NIA NIH HHS / United States
R56 NS050520 / NS / NINDS NIH HHS / United States
R01 AG012101-15 / AG / NIA NIH HHS / United States
R01 EB001015-13A2 / EB / NIBIB NIH HHS / United States
R01 AG022374-03 / AG / NIA NIH HHS / United States
P30 AG008051-199005 / AG / NIA NIH HHS / United States
AG0305 / AG / NIA NIH HHS / United States
R01 AG022374-05 / AG / NIA NIH HHS / United States
Related Institute: 
Brain Health Imaging Institute (BHII)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065